**Core Concept:** Post-transplant lymphoma is a type of non-Hodgkin lymphoma that develops in patients who have undergone solid organ transplantation or hematopoietic stem cell transplantation. This lymphoma is associated with the immune suppression provided by immunosuppressive drugs used to prevent organ rejection.

**Why the Correct Answer is Right:** Post-transplant lymphoma is most commonly associated with hematopoietic stem cell transplantation (HSCT). In HSCT, the patient's immune system is destroyed and replaced with a healthy donor's immune cells. This extreme immune suppression leads to the development of post-transplant lymphoma, as it provides a favorable environment for the expansion of precursor B cells, which are the precursor cells of B-cell lymphomas.

**Why Each Wrong Option is Incorrect:**

A. Liver transplantation: While liver transplantation does involve immune suppression, the risk of post-transplant lymphoma is lower compared to HSCT. This is because liver transplantation primarily suppresses T-cells, which are not directly involved in the development of B-cell lymphomas.

B. Kidney transplantation: Similar to liver transplantation, the risk of post-transplant lymphoma in kidney transplant recipients is relatively low because the primary immune suppression targets T-cells, not B-cells.

C. Solid organ transplantation: Transplanting solid organs like the heart, lung, or pancreas also involves immune suppression, but the risk of post-transplant lymphoma is generally lower than in HSCT or liver/kidney transplantation. This is due to the fact that solid organ transplant recipients primarily receive immunosuppressive drugs that target T-cells, which are not directly involved in the development of B-cell lymphomas.

D. All types of transplantation: The statement "post-transplant lymphoma is common in all types of transplantation" is incorrect. The risk varies greatly among different types of transplantation, as explained above.

**Clinical Pearl:** Post-transplant lymphoma is a well-known complication in recipients of HSCT, particularly allogeneic HSCT, due to the profound immune suppression that targets both T-cells and B-cells. In solid organ transplantation and liver/kidney transplantation, the risk is generally lower, as these procedures primarily suppress T-cells.